Skip to main
BCPC

Balchem (BCPC) Stock Forecast & Price Target

Balchem (BCPC) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Balchem Corp is projected to see strong earnings growth, with GAAP earnings anticipated to rise to $4.73 per diluted share for 2025 and $5.17 per diluted share for 2026, reflecting positive adjustments from previous estimates. The Human Nutrition and Health segment is expected to drive sequential revenue growth, supported by improved gross and net margins, which are forecasted to enhance moving forward. Additionally, with a potentially debt-free status by the end of the year, Balchem's robust balance sheet positions the company well for future accretive mergers and acquisitions to further strengthen its market position.

Bears say

Balchem Corporation’s financial outlook is tempered by a forecasted decline in earnings per diluted share for 2026 to $5.10, down from a prior estimate of $5.17, indicating potential revenue stagnation. Furthermore, the company's Human Nutrition and Health division reported fourth-quarter revenue of $166.1 million, slightly below the projected $170 million, and the Animal Nutrition segment also underperformed with sales of $56.4 million compared to the anticipated $60 million. The overall risks to Balchem's performance include slower growth in core businesses, inflationary pressures, and uncertainties surrounding new product launches and regulatory approvals, which contribute to a cautious view of the stock's future viability.

Balchem (BCPC) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Balchem (BCPC) Forecast

Analysts have given Balchem (BCPC) a Buy based on their latest research and market trends.

According to 2 analysts, Balchem (BCPC) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $176, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $176, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Balchem (BCPC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.